Nimvastid (Rivastigmine)

Rivastigmine reversibly inhibits acetylcholinesterase and butyrylcholinesterase, enzymes that break down acetylcholine. By slowing this breakdown, the drug raises acetylcholine levels at neuronal synapses, supporting the cholinergic pathways that are deficient in Alzheimer’s and Parkinson’s disease dementia.

The exact dose of Nimvastid is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dose titration typically starts low and is increased gradually, but the specific regimen should follow the prescriber’s instructions.

Safety data for rivastigmine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and breastfeeding decisions should be made in consultation with a healthcare professional.

To order Nimvastid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimvastid (rivastigmine) differs from other cholinesterase inhibitors such as donepezil and galantamine by inhibiting both acetylcholinesterase and butyrylcholinesterase, which may offer broader cholinergic enhancement. Its oral formulation is convenient, but side‑effect profiles and dosing schedules vary, so clinicians choose the agent that best matches the patient’s clinical needs.

Nimvastid should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Nimvastid is taken orally, usually with food or a meal to reduce gastrointestinal discomfort. The tablets should be swallowed whole with water and not chewed or crushed unless a specific formulation (e.g., oral solution) is prescribed.

Serious risks include severe bradycardia or heart block, gastrointestinal bleeding or ulceration, significant liver enzyme elevations, and rare allergic reactions such as rash or angioedema. Patients should be monitored for these events, and any concerning symptoms should prompt immediate medical evaluation.

Nimvastid is contraindicated in patients with known hypersensitivity to rivastigmine or any excipients, those with severe cardiac conduction disorders (e.g., sick‑sinus syndrome without a pacemaker), and individuals with active peptic ulcer disease or gastrointestinal bleeding. Caution is also advised for patients with severe renal or hepatic impairment.